555 related articles for article (PubMed ID: 10850286)
1. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
Stein R; Juweid M; Mattes MJ; Goldenberg DM
Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
[TBL] [Abstract][Full Text] [Related]
2. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
3. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.
Juweid M; Sharkey RM; Behr T; Swayne LC; Rubin AD; Hanley D; Herskovic T; Markowitz A; Siegel J; Goldenberg DM
Cancer Res; 1995 Dec; 55(23 Suppl):5946s-5951s. PubMed ID: 7493375
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
Juweid ME; Hajjar G; Swayne LC; Sharkey RM; Suleiman S; Herskovic T; Pereira M; Rubin AD; Goldenberg DM
Cancer; 1999 Apr; 85(8):1828-42. PubMed ID: 10223579
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies.
Juweid M; Sharkey RM; Behr T; Swayne LC; Herskovic T; Pereira M; Rubin AD; Hanley D; Dunn R; Siegel J; Goldenberg DM
J Nucl Med; 1996 Jun; 37(6):905-11. PubMed ID: 8683309
[TBL] [Abstract][Full Text] [Related]
6. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer.
Stein R; Juweid M; Zhang CH; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3199s-3206s. PubMed ID: 10541364
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P
J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
Kraeber-Bodéré F; Faivre-Chauvet A; Saï-Maurel C; Campion L; Fiche M; Gautherot E; Le Boterff J; Barbet J; Chatal JF; Thédrez P
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
[TBL] [Abstract][Full Text] [Related]
10. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
11. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
12. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine.
Stein R; Chen S; Reed L; Richel H; Goldenberg DM
Cancer; 2002 Jan; 94(1):51-61. PubMed ID: 11815960
[TBL] [Abstract][Full Text] [Related]
13. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
Stein R; Goldenberg DM; Thorpe SR; Basu A; Mattes MJ
Cancer Res; 1995 Jul; 55(14):3132-9. PubMed ID: 7606734
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies.
Behr TM; Béhé M; Löhr M; Sgouros G; Angerstein C; Wehrmann E; Nebendahl K; Becker W
Eur J Nucl Med; 2000 Jul; 27(7):753-65. PubMed ID: 10952487
[TBL] [Abstract][Full Text] [Related]
15. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.
Gautherot E; Kraeber-Bodéré F; Daniel L; Fiche M; Rouvier E; Saï-Maurel C; Thedrez P; Chatal JF; Barbet J
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3177s-3182s. PubMed ID: 10541361
[TBL] [Abstract][Full Text] [Related]
16. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
19. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
Stein R; Govindan SV; Hayes M; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Apr; 11(7):2727-34. PubMed ID: 15814655
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen.
Sharkey RM; Kaltovich FA; Shih LB; Fand I; Govelitz G; Goldenberg DM
Cancer Res; 1988 Jun; 48(11):3270-5. PubMed ID: 3365705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]